TheEdgeResearch
Home / Stocks / CBUS

Cibus, Inc. (CBUS)

NASDAQ Healthcare Biotechnology
$1.90 ▼ -0.79%
Market Cap
$145.0M
Sector
Healthcare
Industry
Biotechnology
Beta
1.62
52-Wk Range
1.09-4.191
CEO
Craig Wichner
Country
US
Currency
USD

Cibus, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $1.90, down 0.79% on the session, giving a market capitalisation of $145.0M. On trailing twelve-month figures it carries a trailing P/E of -1.07, a net margin of -2366.3%. Its beta of 1.62 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-1.07
Price / Sales
33.84
Price / Book
34.92
EV / EBITDA
-6.27
Gross margin
72.1%
Operating margin
-1375.7%
Net margin
-2366.3%
Return on equity
Debt / equity
7.78
Current ratio
2.37
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
118
IPO date
2017-07-20
Headquarters
San Diego, CA, US
About Cibus, Inc.

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

Comparable companies

Cibus, Inc. is most often compared with the following Healthcare names:

ACRVBMEACAMPIMUXMNOVPMVPRLMDRPTXUNCYVXRT
More research on CBUS
CBUS technical analysis CBUS TheEdge Score Compare against peers
Open full interactive analysis & DCF →